



NPDA update January 2025



Professor Justin Warner

Consultant in Paediatric Endocrinology and Diabetes, Children's Hospital for Wales, Cardiff, Clinical lead for the NPDA and DUK Clinical Champion



Bwrdd Iechyd Prifysgol Caerdydd a'r Fro
Cardiff and Vale University Health Board



National Paediatric Diabetes
Audit (NPDA) Report on
Care and outcomes 2021/22



National Paediatric Diabetes
Audit (NPDA) Report on Care
and Outcomes 2022/23



National Paediatric Diabetes
Audit (NPDA) 2025 Report on
Care and Outcomes 2023/24




Prevalence paediatric diabetes 2023/24


Country	Total number of children and young people with diabetes	Type 1 diabetes	Type 2 diabetes	Other rare forms
England	33,437	31,190 (93.3%)	1,323 (4.0%)	924 (2.8%)*
Wales	1,685	1,619 (96.1%)	36 (2.1%)	30 (1.8%)*
England and Wales	35,122	32,809 (93.4%)	1,359 (3.9%)	954 (2.7%)*

Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

Total number of CYP receiving care from a PDU 2015/16 – 2023/24




Incidence of Type 1 diabetes per 100,000 general population 0-15 years old in England and Wales, from 2013/14 to 2023/24




Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

Percentage of children and young people with Type 1 diabetes receiving individual health checks, 2015/16 to 2023/24




Health check completion rates by PDU for those with Type 1 diabetes in England and Wales 2023/24



Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

Median HbA1c for CYP with Type 1 diabetes in England and Wales, 2010/11 to 2023/24



Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

NPDA quarterly dashboard

NPDA
National Paediatric
Diabetes Audit

Home

At a glance

Health checks

HbA1c median

Treatment targets

Insulin Pump

CGM

Closed loop system

DKA at diagnosis

DKA post diagnosis

DKA per 100 children




HbA1c median (mmol/mol)

HbA1c provides a measure of blood glucose control over the preceding three months. Lower HbA1c is indicative of more optimal diabetes management, and is associated with a lower risk of diabetes related complications. The median value is presented as it is less affected by extreme values than the mean.

PZ113 University Hospital of Wales

Selected Organisation England and Wales (E&W)



Previous audit year results (mmol/mol)	2023/24 Q1	2023/24 Q2	2023/24 Q3	2023/24 Q4
PZ113 University Hospital of Wales	62	61.5	64	63

Select organisation

pz113

1.PDU

PZ113 University Hospital of ...

cumulative

quarterly

Ethnicity




Deprivation



Age group



Diabetes type




HbA1c median (mmol/mol)
Selected Organisation E&W

HbA1c median (mmol/mol)
Selected Organisation E&W

HbA1c median (mmol/mol)
Selected Organisation E&W


HbA1c median (mmol/mol)
Selected Organisation E&W

Funnel plot of mean adjusted HbA1c by PDU for those with Type 1 diabetes 2023/24




Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

Technology usage and outcome 2021/22 - 2023/24




Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

Mean HbA1c by deprivation quintile for those with Type 1 diabetes, 2013/14- 2023/24




Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

Mean HbA1c by ethnic group CYP Type 1 diabetes 2013/14 – 2023/24




Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

Use of rtCGM by ethnic category and deprivation quintile amongst those with Type 1 diabetes- 2019/20- 2023/24



Please note these findings are from 'NPDA 2023/24 report' that has not yet published and therefore these results may be subject to change and are not for onward sharing

Use of HCL by ethnic category and deprivation quintile 2021/22-2023/24



...and finally




HbA1c median (mmol/mol)

HbA1c provides a measure of blood glucose control over the preceding three months. Lower HbA1c is indicative of more optimal diabetes management, and is associated with a lower risk of diabetes related complications. The median value is presented as it is less affected by extreme values than the mean.

PZ113 University Hospital of Wales

Selected Organisation England and Wales (E&W)



Previous audit year results (mmol/mol)	2023/24 Q1	2023/24 Q2	2023/24 Q3	2023/24 Q4
PZ113 University Hospital of Wales	62	61.5	64	63

Select organisation

🔍 pz113

- 1.PDU
- PZ113 University Hospital of ...

cumulative

quarterly

Ethnicity




Deprivation



Age group



Diabetes type



HbA1c median (mmol/mol)

Selected Organisation E&W

HbA1c median (mmol/mol)

Selected Organisation E&W

HbA1c median (mmol/mol)

Selected Organisation E&W

HbA1c median (mmol/mol)

Selected Organisation E&W

Conclusion

- Dramatic improvements in clinical outcomes for CYP with diabetes in England and Wales in the last 10 years, approaching that seen in some other leading countries, but still work to do.
- Increasing numbers post COVID-19 ? cause
- Use of more advanced technology associated with lower HbA1c
- Inequalities remain a problem but some evidence of stabilisation

The image shows the RCPCH logo in blue, three-dimensional letters mounted on a light-colored stone or concrete wall above a dark doorway. The logo consists of the letters 'R', 'C', 'P', 'C', and 'H'. The second 'C' is stylized with a blue star-like symbol inside it.

RCPCH

Acknowledgements

- RCPCH NPDA Team
- HQIP
- Project Board
- Dataset and Methodology group
- PDU teams/Network managers
- CYP and families living with diabetes

<http://www.rcpch.ac.uk/npda>